Clinical Trials Browser

Recurrence × dostarlimab × Clear all

NCT03981796 2025-09-03

RUBY

Phase 3 Active not recruiting

785 enrolled 4 FDA

Neoplasms, Recurrence

NCT05855811 2024-07-15

PREDOSTAR

Phase 2 Recruiting

Neoplasms, Recurrence, Neoplasms, Second Primary